Informed consent failures appeared across multiple categories of FDA's 1,073 BIMO inspections in FY2023, from missing IRB-required addenda to collecting samples from subjects who explicitly refused consent. The root cause is treating the ICF as a one-time checkbox instead of an ongoing process. FDA guidance is clear: informed consent doesn't end at signature. Sites must update forms when new safety data emerges, initiate re-consent after protocol amendments that change risk profiles, and maintain rigorous version control. Your template must cover 21 CFR 50.25's eight basic elements plus applicable additional elements, align with ICH E6(R3)'s risk-proportionate approach, and increasingly include a key information section up front. Templates that fail to make re-consent obligations visible create downstream compliance risk. The document a subject takes home is both a reference tool and a living record of what was communicated throughout their participation.
Why Your ICF Template Is a Compliance Liability Waiting to…
Regulatory ComplianceInformed ConsentSite Operations
Why Your ICF Template Is a Compliance Liability Waiting to Happen
Informed consent deficiencies remain a top FDA inspection finding. Here's what sites get wrong and how to fix it.
FY2023 FDA Inspections
BIMO inspections conducted1,073
Basic ICF Elements
Required by 21 CFR 50.25(a)8
Key Takeaway
Informed consent is a continuous process, not a signature event. Sites that treat it as a one-time form create compliance risk when protocols change or new safety findings emerge.